🎓 June 30 marks the final day of fellowship for our Class of 2026.
Congratulations to an exceptional group of fellows who have excelled in patient care, research, education, and leadership throughout their training. We are incredibly proud of all they have accomplished and are confident they will continue to make meaningful contributions to oncology and to the patients and communities they serve.
From left to right:
🔹 Dr. Amrit Paudel – Sarcoma & GI Oncology, @SylvesterCancer@univmiami 🔹 Dr. Ali Al Sbihi @Alsbihi93 – GU Oncology, Monument Health (Mayo Clinic Care Network) 🔹 Dr. Traci King – Breast Oncology, Ochsner MD Anderson Cancer Center @OchsnerHealth 🔹Dr. Palash Asawa @palashasawa – Melanoma & GU Oncology, University of Utah Huntsman Cancer Institute @huntsmancancer 🔹 Dr. Chinmay Jani @Jani_Chinmay – Thoracic Oncology & Phase I/Experimental Therapeutics, @SylvesterCancer@univmiami
Congratulations to the Class of 2026! 🎉 We wish you all the very best as you embark on the next chapter of your careers. Your future institutions and, most importantly, your patients are fortunate to have you.
@Drjhoffmanmiami@GlopesMd@SCCCSarcoma@Latinamd@krill_md@GinaDAmatoMD1@EmilyJonczak@JTrentMDPhD@PeterHoseinMD@HemeOnline@JacksonHealth
If there is one cancer where progress is moving fast and living guidelines are needed is #multiplemyeloma. Glad to see this new @ASCO#LivingGuidelines 👇👇👇
Just issued: New living guideline updates on multiple myeloma treatments. For high-risk SMM, management options include active monitoring or daratumumab (up to 36 mos). Lenalidomide is not routinely recommended.
Read the full guideline: https://t.co/JzZdzQbfmA
#Mesothelioma remains “a considerable public health problem” in the US, per @Jani_Chinmay@SylvesterCancer & colleagues.
They found:
📈 Cases & deaths are rising
❌ No survival improvement since 1990
👩 Women bear a growing share of the disease burden https://t.co/KCfe9uEGip
Leaving my baby at @univmiami for her pre-college program and watching her begin to write her own story.
Proud, inspired, and a little emotional as she takes this next step. 💚🧡 #PhysicianMom
¡Nos vemos en Seúl! 🇰🇷 para @IASLC#WCLC26 🫁🌏 Sept 12-15
La conferencia internacional de cáncer de pulmón para aprender, compartir conocimientos, fortalecer colaboraciones y seguir impulsando la ciencia que transforma la vida de nuestros pacientes.
#LungCancer#IASLC #Oncología
The countdown to #WCLC26 is on.
Join the global thoracic oncology community in Seoul to explore the latest research, connect with colleagues from around the world, and help shape the future of lung cancer care.
Register today: https://t.co/3STop8biMh
#IASLC#LungCancer
Congratulations to Caleb Egwuenu, recipient of a 2025 IASLC African Impact Grant!
His project aims to strengthen #lungcancer advocacy and amplify the voices of those affected by the disease.
Join us in celebrating Caleb and this important work!
#CancerAdvocacy#PatientAdvocacy
No te pierdas este panel virtual de @cancerGRACE sobre terapias dirigidas para el cáncer de pulmón. 🫁 Hablaremos sobre los avances más recientes y la importancia de las pruebas de biomarcadores para ofrecer tratamientos personalizados. #CáncerDePulmón#TerapiasDirigidas #MedicinaDePrecisión
🌎 Desde California hasta Florida, expertos en cáncer de pulmón se reunirán para compartir información sobre biomarcadores, mutaciones genéticas y terapias dirigidas.
📅 15 de agosto
💻 Evento virtual y gratuito
👉 Regístrate:
https://t.co/I36hPFZR3g
#CancerDePulmon #TerapiasDirigidas #CancerGRACE
Recorded a virtual tumor board today on ROS1+ lung cancer, highlighting the importance of timely diagnosis, comprehensive biomarker testing, and the evolving treatment landscape. Raising awareness is key to ensuring patients receive the right therapy at the right time. 🫁🔬 #LungCancer #ROS1 #PrecisionMedicine #BiomarkerTesting
Sacituzumab ± Pembro now @US_FDA ✅ in 1L mTNBC based off ASCENT03 & ASCENT04:
- mPFS 9.7 vs 6.9 mos (HR: 0.62) in PDL1-ve
- mPFS 11.2 vs 7.8 mos (HR: 0.65) in PDL1+ve
- ⬆️ORR w/ Saci
- ⬆️ diarrhea & neutropenia w/ Saci
#bcsm#OncTwitter#MedX@OncUpdates@stolaney1 👏👏
Miami has been invaded by the #TartanArmy for a heated🔥 @FIFAWorldCup game tonight Brazil 🇧🇷 vs Scotland 🏴 . We may have to close clinic early today…@GlopesMd
We're proud of @DrJashDatta and our Sylvester team on receiving a highly competitive translational research grant from @TheVFoundation to advance a promising new strategy for pancreatic cancer. Learn more: https://t.co/cFhW5eoOMM.
Published in @JCI_insight, the findings have already helped launch a new Sylvester clinical trial evaluating an IL1RAP-targeted approach in patients with operable pancreatic cancer before surgery, an important step in translating laboratory discoveries into potential new treatment options for patients. 🙌 @PeterHoseinMD
POV: Trying to make a patient fit all the eligibility criteria for a clinical trial today.
#BringPragmaticTrialsBack or at least make more trials for the real world patients we see.
👉🏽Putting a plug here for @eaonc EA5221 trial #ACHIEVE for elderly and poor PS NSCLC @BalazsHalmosMD #clinicaltrials
👏👏Thank you @ASCO for providing a clear statement recommending against a #ivermectin and #fenbendazole for cancer treatment (outside of a clinical trial)
We have a new Clinical Notice recommending against ivermectin & fenbendazole for cancer treatment outside of clinical trials.
Read more: https://t.co/zuzM9uffuu